DK3380487T3 - Additivsystemer til anvendelse i proteinpegylering - Google Patents
Additivsystemer til anvendelse i proteinpegylering Download PDFInfo
- Publication number
- DK3380487T3 DK3380487T3 DK16816042.2T DK16816042T DK3380487T3 DK 3380487 T3 DK3380487 T3 DK 3380487T3 DK 16816042 T DK16816042 T DK 16816042T DK 3380487 T3 DK3380487 T3 DK 3380487T3
- Authority
- DK
- Denmark
- Prior art keywords
- pegyling
- protein
- additional systems
- systems
- additional
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/64—Relaxins
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562258644P | 2015-11-23 | 2015-11-23 | |
PCT/US2016/063313 WO2017091568A1 (en) | 2015-11-23 | 2016-11-22 | Additive systems for use in protein pegylation |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3380487T3 true DK3380487T3 (da) | 2020-12-07 |
Family
ID=57589163
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK16816042.2T DK3380487T3 (da) | 2015-11-23 | 2016-11-22 | Additivsystemer til anvendelse i proteinpegylering |
Country Status (17)
Country | Link |
---|---|
US (3) | US10617765B2 (da) |
EP (2) | EP3380487B1 (da) |
JP (2) | JP6921821B2 (da) |
KR (1) | KR102688003B1 (da) |
CN (2) | CN108350025B (da) |
CY (1) | CY1123699T1 (da) |
DK (1) | DK3380487T3 (da) |
ES (1) | ES2827776T3 (da) |
HR (1) | HRP20201832T1 (da) |
HU (1) | HUE052634T2 (da) |
LT (1) | LT3380487T (da) |
PL (1) | PL3380487T3 (da) |
PT (1) | PT3380487T (da) |
RS (1) | RS61072B1 (da) |
SI (1) | SI3380487T1 (da) |
SM (1) | SMT202000649T1 (da) |
WO (1) | WO2017091568A1 (da) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI3380487T1 (sl) * | 2015-11-23 | 2020-11-30 | Bristol-Myers Squibb Company | Sistemi dodatkov za uporabo pri pegilaciji proteinov |
US12049485B2 (en) * | 2018-09-11 | 2024-07-30 | Ambrx, Inc. | Interleukin-2 polypeptide conjugates and their uses |
CN111484551B (zh) * | 2020-03-19 | 2022-02-11 | 北京翼方生物科技有限责任公司 | 一种聚乙二醇修饰的重组人碱性成纤维细胞生长因子 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19535571A1 (de) | 1995-09-14 | 1997-03-20 | Boehringer Mannheim Gmbh | Pharmazeutische Kombinationspräparate und deren Verwendung zur Behandlung von Hämodialysepatienten |
TWI240627B (en) | 1996-04-26 | 2005-10-01 | Chugai Pharmaceutical Co Ltd | Erythropoietin solution preparation |
EP0885613A1 (de) | 1997-06-21 | 1998-12-23 | Roche Diagnostics GmbH | Verwendung von modifizierten Hämoglobinen zur Behandlung von Anämien und Kombinationspräparate umfassend Erythropoietin und modifiziertes Hämoglobin |
DE19734293A1 (de) | 1997-08-08 | 1999-02-11 | Boehringer Mannheim Gmbh | Verwendung von pharmazeutischen Kombinationspräparaten enthaltend Erythropoietin und Eisenpräparate zur Behandlung von rheumatischen Erkrankungen |
KR101245071B1 (ko) * | 2004-03-17 | 2013-03-18 | 안티캔서, 인코포레이티드 | 폴리에틸렌 글리콜(peg) 단백질 결합을 증가시키기 위한방법 |
JP2008545754A (ja) * | 2005-06-01 | 2008-12-18 | アルザ・コーポレーシヨン | ポリエチレングリコール試薬をアシル化するためのバイオコンジュゲーション反応 |
PT1954710E (pt) * | 2005-11-08 | 2011-06-07 | Ambrx Inc | Aceleradores para a modificação de aminoácidos nãonaturais e polipeptídeos de aminoácidos não-naturais |
KR20140012199A (ko) * | 2007-03-30 | 2014-01-29 | 암브룩스, 인코포레이티드 | 변형된 fgf-21 폴리펩티드 및 그 용도 |
KR102363779B1 (ko) | 2013-01-30 | 2022-02-15 | 아벨라스 바이오사이언시즈 인코포레이티드 | 선택적 전달 분자 및 사용 방법 |
WO2014176284A1 (en) | 2013-04-22 | 2014-10-30 | Avelas Biosciences, Inc. | Selective drug delivery compositions and methods of use |
MX2017004947A (es) | 2014-10-24 | 2017-06-29 | Bristol Myers Squibb Co | Polipeptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos. |
SI3380487T1 (sl) * | 2015-11-23 | 2020-11-30 | Bristol-Myers Squibb Company | Sistemi dodatkov za uporabo pri pegilaciji proteinov |
-
2016
- 2016-11-22 SI SI201630957T patent/SI3380487T1/sl unknown
- 2016-11-22 PT PT168160422T patent/PT3380487T/pt unknown
- 2016-11-22 CN CN201680067897.7A patent/CN108350025B/zh active Active
- 2016-11-22 JP JP2018526713A patent/JP6921821B2/ja active Active
- 2016-11-22 RS RS20201382A patent/RS61072B1/sr unknown
- 2016-11-22 PL PL16816042T patent/PL3380487T3/pl unknown
- 2016-11-22 EP EP16816042.2A patent/EP3380487B1/en active Active
- 2016-11-22 LT LTEP16816042.2T patent/LT3380487T/lt unknown
- 2016-11-22 HU HUE16816042A patent/HUE052634T2/hu unknown
- 2016-11-22 EP EP20189107.4A patent/EP3789395A1/en active Pending
- 2016-11-22 SM SM20200649T patent/SMT202000649T1/it unknown
- 2016-11-22 CN CN202211743414.4A patent/CN115819494A/zh active Pending
- 2016-11-22 KR KR1020187017508A patent/KR102688003B1/ko active Active
- 2016-11-22 ES ES16816042T patent/ES2827776T3/es active Active
- 2016-11-22 DK DK16816042.2T patent/DK3380487T3/da active
- 2016-11-22 WO PCT/US2016/063313 patent/WO2017091568A1/en active Application Filing
- 2016-11-22 US US15/776,923 patent/US10617765B2/en active Active
-
2020
- 2020-02-21 US US16/797,361 patent/US11213589B2/en active Active
- 2020-11-19 HR HRP20201832TT patent/HRP20201832T1/hr unknown
- 2020-11-20 CY CY20201101102T patent/CY1123699T1/el unknown
-
2021
- 2021-07-28 JP JP2021123154A patent/JP7257457B2/ja active Active
- 2021-12-03 US US17/541,636 patent/US20220160883A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
LT3380487T (lt) | 2020-12-28 |
JP2021176890A (ja) | 2021-11-11 |
CY1123699T1 (el) | 2022-03-24 |
EP3380487A1 (en) | 2018-10-03 |
HUE052634T2 (hu) | 2021-05-28 |
EP3789395A1 (en) | 2021-03-10 |
SI3380487T1 (sl) | 2020-11-30 |
HRP20201832T1 (hr) | 2021-01-08 |
PL3380487T3 (pl) | 2020-12-28 |
US20190351065A1 (en) | 2019-11-21 |
WO2017091568A8 (en) | 2018-01-04 |
WO2017091568A1 (en) | 2017-06-01 |
CN108350025B (zh) | 2023-02-21 |
US10617765B2 (en) | 2020-04-14 |
US20200276319A1 (en) | 2020-09-03 |
US11213589B2 (en) | 2022-01-04 |
US20220160883A1 (en) | 2022-05-26 |
CN115819494A (zh) | 2023-03-21 |
KR20180081610A (ko) | 2018-07-16 |
KR102688003B1 (ko) | 2024-07-23 |
RS61072B1 (sr) | 2020-12-31 |
JP2019503994A (ja) | 2019-02-14 |
PT3380487T (pt) | 2020-10-29 |
JP6921821B2 (ja) | 2021-08-18 |
SMT202000649T1 (it) | 2021-01-05 |
ES2827776T3 (es) | 2021-05-24 |
EP3380487B1 (en) | 2020-09-02 |
JP7257457B2 (ja) | 2023-04-13 |
CN108350025A (zh) | 2018-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL254516A0 (en) | Proteins specific for cd137 | |
IL248770A0 (en) | A trading system | |
DK3569525T3 (da) | Opbevaringssystem | |
DK3265421T3 (da) | Doseringssystem | |
EP3161481C0 (en) | GLOBAL WELL-BEING EVALUATION SYSTEM | |
HUE048645T2 (hu) | Összekötõ- és tartályrendszer | |
DK3197453T3 (da) | Kimært protein | |
DK2966740T3 (da) | Jævnstrømssystem til flådeanvendelser | |
EP3431417C0 (de) | Lagersystem | |
IL233902B (en) | Propulsion system | |
DK4089113T3 (da) | Polypeptider | |
DK3195160T3 (da) | Computerstyret doseringssystem | |
DK4019731T3 (da) | Taper-LOC Systemforbedringer | |
DK3145946T3 (da) | Bakteriebaseret proteintilførsel | |
EP3310319C0 (en) | CONNECTION AND CONTAINER SYSTEM | |
DK3262168T3 (da) | Værtscelleproteinmodifikation | |
DK3177800T3 (da) | Brøndventilsystem | |
DK3377634T3 (da) | Bakteriebaseret proteinafgivelse | |
DK3640164T3 (da) | Justerbare transportørsystemer | |
DK3702450T3 (da) | Protein | |
DK3259358T3 (da) | Forøget proteinekspression | |
DK3288955T3 (da) | Bortezomib-baseret afgivelsessystem | |
EP3328438A4 (en) | POLYPEPTIDE MONOLITH | |
DK3132031T3 (da) | Carbohydratbindende protein | |
DK3271724T3 (da) | Anvendelse af en standard til påvisning af proteinaggregater i en proteinfejlfoldningssygdom |